DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,117 filers reported holding DANAHER CORPORATION in Q3 2017. The put-call ratio across all filers is 0.49 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $237,860,548 | -8.2% | 951,589 | -8.3% | 0.38% | -6.4% |
Q1 2024 | $258,986,185 | +15.5% | 1,037,316 | +7.1% | 0.41% | +2.5% |
Q4 2023 | $224,245,926 | +4.6% | 968,947 | +12.1% | 0.40% | -5.9% |
Q3 2023 | $214,375,873 | +18.5% | 864,320 | +14.6% | 0.42% | +21.5% |
Q2 2023 | $180,868,914 | -3.1% | 754,277 | +1.9% | 0.35% | -4.6% |
Q1 2023 | $186,610,123 | -2.2% | 740,452 | +3.0% | 0.37% | -6.9% |
Q4 2022 | $190,797,256 | +22.0% | 718,818 | +18.7% | 0.39% | +14.2% |
Q3 2022 | $156,375,000 | -1.4% | 605,347 | -3.2% | 0.34% | +6.5% |
Q2 2022 | $158,534,000 | -18.2% | 625,372 | -5.3% | 0.32% | -4.2% |
Q1 2022 | $193,723,000 | -17.2% | 660,342 | -7.1% | 0.34% | -9.9% |
Q4 2021 | $233,838,000 | +14.8% | 710,769 | +6.3% | 0.37% | +8.7% |
Q3 2021 | $203,644,000 | +10.3% | 668,859 | -2.7% | 0.34% | +11.3% |
Q2 2021 | $184,596,000 | +30.0% | 687,540 | +9.0% | 0.31% | +23.1% |
Q1 2021 | $141,947,000 | +33.6% | 630,830 | +31.8% | 0.25% | +19.5% |
Q4 2020 | $106,219,000 | -13.4% | 478,701 | -16.3% | 0.21% | -20.5% |
Q3 2020 | $122,613,000 | +8.9% | 572,066 | -10.6% | 0.26% | +5.2% |
Q2 2020 | $112,574,000 | +22.1% | 640,134 | -3.6% | 0.25% | +5.0% |
Q1 2020 | $92,193,000 | +16.0% | 664,246 | +28.2% | 0.24% | +61.5% |
Q4 2019 | $79,447,000 | -4.4% | 518,050 | -10.4% | 0.15% | -8.1% |
Q3 2019 | $83,110,000 | +55.6% | 577,989 | +54.3% | 0.16% | +61.0% |
Q2 2019 | $53,422,000 | +5.7% | 374,622 | -2.8% | 0.10% | +7.5% |
Q1 2019 | $50,535,000 | +27.9% | 385,290 | +0.0% | 0.09% | +5.7% |
Q4 2018 | $39,516,000 | -31.4% | 385,115 | -27.5% | 0.09% | -19.3% |
Q3 2018 | $57,593,000 | +47.7% | 530,963 | +34.3% | 0.11% | +34.6% |
Q2 2018 | $39,006,000 | -34.0% | 395,430 | -34.6% | 0.08% | -19.0% |
Q1 2018 | $59,108,000 | +15.0% | 604,511 | +10.0% | 0.10% | +16.3% |
Q4 2017 | $51,402,000 | +2.7% | 549,550 | -5.8% | 0.09% | +1.2% |
Q3 2017 | $50,027,000 | -41.3% | 583,273 | -42.3% | 0.08% | -43.7% |
Q2 2017 | $85,257,000 | +26.1% | 1,010,160 | +27.7% | 0.15% | +21.8% |
Q1 2017 | $67,630,000 | +30.3% | 790,779 | +19.2% | 0.12% | +22.8% |
Q4 2016 | $51,898,000 | – | 663,529 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |